Akebia Therapeutics (NASDAQ: AKBA) reported Q1 EPS of ($0.47), $0.15 better than the analyst estimate of ($0.62). Revenue for the quarter came in at $88.5 million versus the consensus estimate of $77.48 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.